Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Histac

(Ranitidine Hydrochloride Tablets)


COMPOSITION
HISTAC 150 mg  : Each film-coated tablet contains :
Ranitidine Hydrochloride BP equivalent to Ranitidine 150 mg

HISTAC 300 mg : Each film-coated tablet contains :
Ranitidine Hydrochloride BP equivalent to Ranitidine 300 mg


PRODUCT DESCRIPTION
HISTAC 150 mg : Creamish-yellow, round biconvex film-coated tablets embossed with "HISTAC 150" on one side, and "RANBAXY" on the other side.

HISTAC 300 mg Creamish-yellow, capsule shaped biconvex film-coated tablets embossed with "HISTAC 300" on one side, and stomach sign on other side.


DESCRIPTION
HISTAC contains Ranitidine Hydrochloride which is a histamine H2 antagonist. Chemically, it is N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]sulphanyl]ethyl]-N1-methyl-2-nitroethene-1,1-diamine hydrochloride. Its empirical formula is C13H22,N4,O3,S, HCI and its molecular weight is 350.9. The chemical structure of Ranitidine HCI is as follows:

 

Histac


PHARMACOLOGY (SUMMARY OF PHARMACODYNAMICS AND PHARMACOKINETICS)
Ranitidine is a specific, rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume, the acid and pepsin content of the secretion. Ranitidine has a relatively long duration of action and so a single 150 mg dose effectively suppresses gastric secretion for twelve hours.

The bioavailability of Ranitidine is consistently about 50%. Absorption of Ranitidine after oral administration is rapid and peak plasma concentrations are usually achieved in 2-3 hours after administration. Absorption is not significantly impaired by food or antacids. Ranitidine is not extensively metabolised.

Elimination of the drug is primarily by tubular secretion. The elimination half-life of Ranitidine is 2-3 hours. After an oral administration of 150 mg Ranitidine, 60-70% is excreted in urine and 26% in faeces. About 35% of the oral dose is eliminated unchanged and 6% of the dose is excreted as the N-oxide, 2% as the S-oxide, 2% as desmethyl Ranitidine and 1-2% as furoic acid analogue.

 

INDICATIONS
Ranitidine tablets BP are indicated for the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. In addition, Ranitidine tablets are indicated for the prevention of NSAID associated duodenal ulcers.


Ranitidine tablets are also indicated for the treatment of post-operative ulcer, Zollinger-Ellison syndrome and oesophageal reflux disease including the long term management of healed oesophagitis. Other patients with chronic episodic dyspepsia, characterized by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but not associated with the preceding conditions may benefits from Ranitidine treatment. Ranitidine tablets are indicated for the following conditions where reduction of gastric secretion and acid output is desirable : prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients, prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers and before general anaesthesia in patients considered to be at risk of acid aspiration (Mandelson's syndrome), particularly obstetric patients during labour.


CONTRAINDICATIONS
Ranitidine is contraindicated for patients known to have hypersensitivity to the drug.

 

SIDE EFFECTS /ADVERSE EFFECTS
Transient and reversible changes in liver function tests can occur. There have been occasional reports of hepatitis (hepatocellular, hepatocanalicular or mixed) with or without jaundice. These were usually reversible. Acute pancreatitis has been reported rarely.


Leucopenia, thrombocytopenia, agranulocytosis or pancytopenia, sometimes with marrow hypoplasia, or aplasia have been reported.


Hypersensitivity reactions (urticaria, angioneurotic oedema, fever, bronchospasm, hypotension, anaphylactic shock) have been seen rarely following an oral administration of Ranitidine. These reactions have occasionally occurred after a single dose.


As with other H2-receptor antogonists, there have been rare reports of bradycardia and A-V block.


Headache, sometimes severe, and dizziness have been reported in a very small proportion of patients. Rare cases of reversible mental confusion, depression and hallucinations have been reported, predominantly in severely ill and elderly patients.


Skin rash and musculoskeletal symptoms such as arthralgia and myalgia have been reported rarely.


No clinically significant interference with endocrine or gonadal function has been reported. There have been a few reports of breast symptoms (swelling and / or discomfort) in men taking Ranitidine; some cases have resolved on continued Ranitidine treatment. Discontinuation of therapy may be necessary in order to establish the underlying cause.

WARNINGS / PRECAUTIONS / DRUG INTERACTIONS
Treatment with a histamine H2 antagonist may mask symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition. Accordingly, where gastric ulcer has been diagnosed or in patients of middle age and over with new or recently changed dyspeptic symptoms, the possibility of malignancy should be excluded before therapy with Ranitidine Tablets.


Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with severe renal impairment. It is recommended that the dose of Ranitidine in such patients be 150 mg at night for 4 to 8 weeks. The same dose should be used for maintenance. If an ulcer has not healed after treatment the standard dosage regimen of 150 mg twice daily should be instituted, followed by maintenance treatment of 150 mg at night.

 

Regular supervision of patients who are taking non-steroidal anti-inflammatory drugs concomitantly with Ranitidine is recommended, especially in the elderly.

Ranitidine crosses the placenta but therapeutic doses administered to obstetric patients in labour or undergoing caesarean section have been without any adverse effect on labour, delivery of subsequent neonatal progress. Ranitidine is also excreted in human breast milk.

Like other drugs, Ranitidine should only be used during pregnancy and nursing if considered essential.

Ranitidine should be avoided in patients with a history of Acute intermittent porphyria.

Use in elderly patients.

There is no evidence suggesting limitation of usefulness in elderly.

1    2

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer